chemotherapy adjuvant
Recently Published Documents


TOTAL DOCUMENTS

23
(FIVE YEARS 10)

H-INDEX

4
(FIVE YEARS 0)

2021 ◽  
Vol 22 (23) ◽  
pp. 13072
Author(s):  
Ana S. Serras ◽  
Sérgio P. Camões ◽  
Bernardo Antunes ◽  
Vera M. Costa ◽  
Flávio Dionísio ◽  
...  

Doxorubicin (Dox) is one of the most widely used treatments for breast cancer, although limited by the well-documented cardiotoxicity and other off-target effects. Mesenchymal stem cell (MSC) secretome has shown immunomodulatory and regenerative properties, further potentiated under 3D conditions. This work aimed to uncover the effect of the MSC-derived secretome from 3D (CM3D) or 2D (CM2D) cultures, in human malignant breast cells (MDA-MB-231), non-tumor breast epithelial cells (MCF10A) and differentiated AC16 cardiomyocytes, co-treated with Dox. A comprehensive proteomic analysis of CM3D/CM2D was also performed to unravel the underlying mechanism. CM3D/CM2D co-incubation with Dox revealed no significant differences in MDA-MB-231 viability when compared to Dox alone, whereas MCF10A and AC16 viability was consistently improved in Dox+CM3D-treated cells. Moreover, neither CM2D nor CM3D affected Dox anti-migratory and anti-invasive effects in MDA-MB-231. Notably, Ge-LC-MS/MS proteomic analysis revealed that CM3D displayed protective features that might be linked to the regulation of cell proliferation (CAPN1, CST1, LAMC2, RANBP3), migration (CCN3, MMP8, PDCD5), invasion (TIMP1/2), oxidative stress (COX6B1, AIFM1, CD9, GSR) and inflammation (CCN3, ANXA5, CDH13, GDF15). Overall, CM3D decreased Dox-induced cytotoxicity in non-tumor cells, without compromising Dox chemotherapeutic profile in malignant cells, suggesting its potential use as a chemotherapy adjuvant to reduce off-target side effects.


2021 ◽  
Vol 22 (18) ◽  
pp. 9766
Author(s):  
Chin-Chuan Chen ◽  
Chi-Yuan Chen ◽  
Shu-Fang Cheng ◽  
Tzong-Ming Shieh ◽  
Yann-Lii Leu ◽  
...  

Molecules involved in DNA damage response (DDR) are often overexpressed in cancer cells, resulting in poor responses to chemotherapy and radiotherapy. Although treatment efficacy can be improved with the concomitant use of DNA repair inhibitors, the accompanying side effects can compromise the quality of life of patients. Therefore, in this study, we identified a natural compound that could inhibit DDR, using the single-strand annealing yeast-cell analysis system, and explored its mechanisms of action and potential as a chemotherapy adjuvant in hepatocellular carcinoma (HCC) cell lines using comet assay, flow cytometry, Western blotting, immunofluorescence staining, and functional analyses. We developed a mouse model to verify the in vitro findings. We found that hydroxygenkwanin (HGK) inhibited the expression of RAD51 and progression of homologous recombination, thereby suppressing the ability of the HCC cell lines to repair DNA damage and enhancing their sensitivity to doxorubicin. HGK inhibited the phosphorylation of DNA damage checkpoint proteins, leading to apoptosis in the HCC cell lines. In the mouse xenograft model, HGK enhanced the sensitivity of liver cancer cells to doxorubicin without any physiological toxicity. Thus, HGK can inhibit DDR in liver cancer cells and mouse models, making it suitable for use as a chemotherapy adjuvant.


2021 ◽  
pp. BMT56
Author(s):  
Natalia Camejo ◽  
Cecilia Castillo ◽  
Andrea Schiavone ◽  
Ana L Alfonso ◽  
Dahiana Amarillo ◽  
...  

Male breast cancer (MBC) is a rare condition which, while sharing some similarities with breast cancer in women, has a unique disease profile of its own. Aim: To understand the characteristics of MBC and its management in Uruguay. Patients & methods: Retrospective observational study that included patients diagnosed with MBC. Results: 22 cases of MBC were found. The median age at diagnosis was 62.5 years. Symptoms included self-detected lump in 17 patients (77.3%) and nipple retraction in seven (22.7%). Ductal carcinomas of histological grade 2–3 were found in 20 patients (90.9%) and stage I–II disease was most commonly encountered (15 patients, 68.1%). Neoadjuvant chemotherapy, adjuvant chemotherapy, adjuvant radiotherapy and tamoxifen were offered to 16 (73%), 12 (54.5%), 17 (65.4%) and 20 (90.9%) patients, respectively. Conclusion: MBC behaves and is treated in many aspects like postmenopausal breast cancer. Further multi-institutional, prospective studies are needed for better understanding and management of male breast cancers.


2021 ◽  
Vol 16 (3) ◽  
pp. S58-S59
Author(s):  
S. Novello ◽  
V. Monica ◽  
M. Serke ◽  
C. Grohe ◽  
A. Meyer ◽  
...  

Author(s):  
Seema Devi ◽  
Yogesh Kumar Sharma

Breast cancer is second leading cause of death in women. Treatment modalities for breast cancer optimized according to stage at which the cancer is diagnosed. Chemotherapy, hormone therapy   and targeted therapies are used for the treatment of advanced stages of disease. The aim of therapy different like to enhancing the curative rate in adjuvant therapy, reduce symptoms or  improve quality of life in metastatic diseases, reduce the chances of the cancer coming Back. The complications of therapy including mental function; cardiovascular functions; neuromusculoskeletal and movement related functions and structures functions of hematological immunological and respiratory system etc. The benefits of chemotherapy are limited and relative compared to the risk factors. Chemotherapeutic agents use in treatment of breast cancer such as taxanes (docetaxel and paclitaxel), tamoxifen , vincristine, cyclophosphamide, trastuzumab etc. Keyword: breast cancer, hormone therapy, targeted therapy, chemotherapy, adjuvant therapy.


2020 ◽  
Vol 8 (5) ◽  
pp. 259-261
Author(s):  
Thomas Lesser

Background: The NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology (NCCN guidelines) recommend radical resection for T1–2N0M0 patients with limited-stage small cell lung cancer (LS-SCLC). However, only about 5% of patients with small cell cancer (SCLC) were initially diagnosed as T1–2N0M0. The purpose of our study was to analyze and compare the effects of the comprehensive treatment including radical surgery and concurrent chemoradiotherapy on the prognosis of patients with LS-SCLC. Methods: We comprehensively reviewed the medical data of patients with SCLC diagnosed by pathology in our hospital from January 2011 to April 2018. The Ethics Committee of West China Hospital of Sichuan University approved the study. Finally, 50 patients with good follow-up and complete medical data were selected as the surgical group (S group). According to the clinical characteristics of the patients in the S group, 102 LS-SCLC patients who received concurrent chemoradiotherapy in the same period were included in the CCRT group (concurrent chemoradiotherapy group) as the control group. Then according to the orders of the adjuvant treatments, the patients in the S group were divided into the SA group (radical surgery + adjuvant chemotherapy + adjuvant radiotherapy group, 30 cases in total) and the NS group (neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy ± adjuvant radiotherapy group, 20 cases in total) for subgroup analysis. The SPSS 23.0 software was used for statistical analysis, and the t test was used for group comparison; Kaplan-Meier was used for survival analysis. P < 0.05 demonstrates a statistically significant difference. Results: The median progress-free survival (PFS) in the S group (73 months) was significantly better than that in the CCRT group (10.5 months, P < 0.0001), and the median overall survival (OS) in the S group (79 months) was also significantly better than that in the CCRT group (23 months, P < 0.0001). Subgroup analysis showed that there was no significant difference between the NS group and the SA group. Conclusions: For LS-SCLC patients, the comprehensive treatment including radical surgery (radical surgery + adjuvant chemotherapy ± adjuvant radiotherapy/neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy ± adjuvant radiotherapy) may be superior to concurrent chemoradiotherapy.


2019 ◽  
Vol 2 (3) ◽  
pp. 117-122
Author(s):  
Deri Edianto

The aim of this study is to evaluate response of cervical cancer stage IB – IIA after neoadjuvant chemotherapy based on VEGF expression. The data were collected from 51 patients’ cervical cancer stage IB – IIA parafin blocks who received chemotherapy ifosfamide – cisplatin before radical hysterectomy at General Hospital Adam Malik Medan. VEGF expression was evaluated from cervical biopsy tissue, and response therapy was evaluated based on tumor size clinically. 20 out of 51 samples with clinically complete response, and the rest are partial response. 18 out of 20 samples with clinically complete response have negative or weak VEGF expression, and 31 out of 51 samples patients were partialy response with moderate or strong VEGF expression. 23 cases with tumor size > 4 cm and 23 cases stage IIA expressed VEGF moderately or strong. Cervical cancer with tumor size < 4 cm and cervical cenncer stage IB with less expressed of VEGF have good response with chemotherapy adjuvant ifosfamide – cis platin.Keyword: ifosfamide-cisplatin, cervical cancer, VEGF


2019 ◽  
Author(s):  
Yong-Jae Kim ◽  
Jinseon Jeong ◽  
Ki-Young Sohn ◽  
Do Young Lee ◽  
Sun Young Yoon ◽  
...  

2019 ◽  
Author(s):  
Yong-Jae Kim ◽  
Jinseon Jeong ◽  
Ki-Young Sohn ◽  
Do Young Lee ◽  
Sun Young Yoon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document